Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...

His devastating diagnosis came after a routine eye examination and subsequent investigations.

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

Oculis Holding AG (OCS) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 4:30 PM ESTCompany ParticipantsRiad Sherif - CEO ...

For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging advances, from gene editing and stem cells to microchips and laser-based ...

Oculis Holding AG, a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, announced that its ...

Please provide your email address to receive an email when new articles are posted on . If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies. The PIONEER 1 ...

Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for its eye disease therapy Privosegtor as a treatment for optic neuritis (ON), ...

Oculis Holding AG recently reported that its neuroprotective candidate Privosegtor received U.S. FDA Breakthrough Therapy designation for optic neuritis, supported by positive Phase 2 ACUITY data and ...